结直肠癌化疗的研究进展  

Research proggresion of chemotherapy to colorectal cancer

作　　者：石会勇[1] 徐忠法[1] 

机构地区：[1]山东省医学科学院附属医院普外科,山东济南250117

出　　处：《中华肿瘤防治杂志》2012年第24期1915-1918,共4页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:对结直肠癌(CRC)化疗的新进展进行综述分析。方法:应用PubMed、CNKI数据库和ASCO论文集等检索系统,以"结肿瘤、直肠肿瘤和化疗"为检索词,检索2005-01-2012-06的相关文献,共检索到英文文献303篇,中文文献78篇。文献纳入标准:1)结直肠肿瘤;2)药物治疗;3)大型的随机对照临床试验;4)排除单中心、小样本试验结果。根据纳入标准符合分析文献31篇。结果:CRC的辅助化疗、新辅助化疗、转移性CRC的化疗及靶向治疗方面均取得了显著进展。随着新一代化疗药物的出现,奥沙利铂、氟尿嘧啶、伊立替康、希罗达及分子靶向药物西妥昔单抗、贝伐单抗等组成的多种化疗方案使得CRC患者的生存期、无病生存期及缓解率得到了明显改善,毒副作用进一步降低。结论:CRC的化疗向着规范化及基于分子靶向的个体化治疗方向发展,终将使患者更好的临床获益。OBJECTIVE： To review the new advancements of chemotherapy to colorectal cancer（CRC）. METHOD： Retrieve keywords such as “colorectal cancer or colorectal carcinoma and chemotherapy” on PubMed, CNKI and ASCO proceedings from 2005-01 to 2012-06. Totally 303 English articles and 78 Chinese articles were obtained. Inclusion crite- ria： 1） colorectal neoplasms; 2） drug therapy; 3） large clinical test with random contrast; 4） eliminate clinical test with single centrality and small specimen. According to the inclusion criteria, 31 articles were finaly analyzed. RESULTS： CRC treatments such as adjuvant, new adjuvant chemotherapy, metastatic neoplasm chemotherapy and targeted therapy all de- rived significant advancement. By appearance of new chemo drugs, Oxaliplatin, Fluorouracil, CPT-11, Xeloda and molecular targeted drugs like Cetuximab,Bevacizumab combined proposal have significant improved survival period and correspond- ing rates,and adverse reaction decreased. CONCLUSION： CRC chemotherapy is developed to standardization and individu alization,which will give the patients more clinical benefit.

关 键 词：结直肠肿瘤 药物疗法 综述文献 

分 类 号：R735.3[医药卫生—肿瘤]